Infex Therapeutics secures £4.3m in funding led by Jon Moulton for antimicrobial resistance treatments

Infex Therapeutics is an anti-infectives specialist developing treatments for antimicrobial resistance and other infectious diseases. Its pipeline includes programmes targeting drug-resistant Gram-negative infections and respiratory infections caused by Pseudomonas aeruginosa.